abc biopply enters into a strategic partnership with Quadira Biosciences, to create a sustainable concept for the development of highly effective therapeutic antibodies without animal testing
Swiss biotech company abc biopply enters into a strategic partnership with Quadira Biosciences, which was founded as a joint venture by Xlife Sciences AG and anfass Life Technologies AG. Quadira Biosciences thereby gains access to the proprietary 3D CoSeedis™ technology platform of abc biopply. This unique 3D cell technology enables the replication and modelling of human tissue for reliable testing and characterization of antibodies without animal testing. Xlife's technology platform for antibody development can thus be used even more efficiently.
With its antibody screening platform, Xlife Sciences AG has already identified 30 compounds with blockbuster potential. These therapeutic antibodies have already been shown to be safe and effective in humans. Xlife can modify antibodies with pinpoint accuracy and increase the quality of the active components. These are mainly advanced, highly potent antibodies with higher cytotoxic activity and improved side effect profiles for cancer therapy. The targeted market potential of the pre-selected antibodies is in the range of several billion US dollars.
The collaboration with abc biopply adds an important element to the development process. The 3D CoSeedis™ technology platform developed by abc biopply allows the testing and characterization of the efficacy of antibodies in 3D cell cultures, so-called organoids, that mimic animal or human tissue. This reduces or even eliminates animal testing and significantly accelerates product development. 3D CoSeedis™ is characterized by the unique homogeneity of the generated spheroids and enables their standardized mass production. Ultimately, this massively simplifies preclinical disease modeling. The partnership with Quadira Bioscience now creates a sustainable concept that could revolutionize cancer therapy.
About abc biopply ag
abc biopply ag is a Swiss biotech company specializing in the standardization of biological components and complex 3D cell culture systems. With its proprietary 3D CoSeedis™ technology platform, which enables the mass production of uniquely homogeneous and uniform spheroids/organoids, the company has set a new standard in the industrial application of 3D cell culture systems. Through the innovative possibility of distance co-cultivation of 3D tissue structures, abc biopply also offers systems for the study of complex organ-to-organ communication and also performs corresponding analyses with its 3D Lab Services on a contract basis. For more information, visit: www.biopply.com
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company focused on the value development of promising technologies in the life science sector. The company bridges the gap between research and development and the healthcare markets. Together with industrial partners or university institutions, the company leads projects through the proof of concept phase after an invention disclosure or spin-off. Xlife Sciences AG thus provides its investors with a very early and direct entry into the further development of innovative and future-oriented technologies. Further information: www.xlifesciences.ch
Information for the media:
Arne-C. Faisst, CEO abc biopply ag, Mobile +41 79 434 10 49, arne.faisst@biopply.com